| http://www.w3.org/ns/prov#value | - Teva says that Ratiopharm has 'valuable know-how in biosimilars, consisting of a number of products in advanced stages of development', and that the transaction is 'perfectly aligned with our long-term strategy in which Europe is an important pillar and growth driver'.
|
